A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and chlorthalidone in Hypertension, sponsored by Takeda. Completed at 99 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-07.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.
Among the 21 studies testing azilsartan medoxomil in Hypertension, this one has the largest enrollment, is one of 4 that started in 2009, is one of 17 in phase 3, and was the 13th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Gedeon Richter Plc. · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2009.
This study's enrollment of 1,711 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 566 across the 21 interventional studies. Of the 20 that completed or were terminated, 20 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 3 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
44 studies in Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 44 studies in Hypertension by Takeda, this one has the largest enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2009, is one of 25 in phase 3, and was the 18th registered.
Takeda’s Hypertension studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing azilsartan medoxomil in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 44 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.
According to the World Health Organization (WHO), hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully.
Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker that is being evaluated by Takeda to treat essential hypertension.
Treatments for essential hypertension commonly include use of a thiazide-like diuretic, either alone or as part of combination treatment.
This study is designed to compare the antihypertensive effect and the safety and tolerability of the azilsartan medoxomil plus chlorthalidone fixed-dose combination product (TAK 491CLD FDC) with azilsartan monotherapy and chlorthalidone monotherapy during 8 weeks of treatment.
Participants in this study will be randomized to receive one of 11 possible dosing combinations of azilsartan medoxomil , chlorthalidone and placebo over an 8 week period. The total duration of the study will be approximately 13 weeks. Participants will make 12 visits to the clinic. Each participant will also be contacted by telephone 14 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Chlorthalidone
Drug: Chlorthalidone
Drug: Azilsartan medoxomil
Drug: Azilsartan medoxomil
Drug: Azilsartan medoxomil
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Also known as: TAK-491CLD
Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)
The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)
The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure
The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.
The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 8.
Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.
The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 8
Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.
The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 8.
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.
Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements.
Time frame: Baseline and Week 8
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.
Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements.
Time frame: Baseline and Week 8.
Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.
Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements.
Time frame: Baseline and Week 8.
Participants enrolled at 175 investigative sites in Austria, Chile, Germany, Guatemala, Mexico, Netherlands, Peru, Poland, Russian Federation and the United States from 29 January 2009 to 10 July 2010.
| Milestone | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 156 | 154 | 147 | 156 | 153 | 162 | 157 | 160 | 155 | 153 | 162 |
| Completed | 135 | 131 | 131 | 125 | 125 | 125 | 135 | 141 | 141 | 139 | 142 |
| Not completed | 21 | 23 | 16 | 31 | 28 | 37 | 22 | 19 | 14 | 14 | 20 |
| Withdrew: Adverse event | 10 | 10 | 6 | 19 | 11 | 22 | 4 | 6 | 3 | 6 | 6 |
| Withdrew: Protocol violation | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 | 0 | 3 | 1 | 3 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 5 | 3 | 8 | 12 | 9 | 8 | 4 | 4 | 5 | 2 |
| Withdrew: Lack of efficacy | 3 | 1 | 0 | 1 | 2 | 0 | 6 | 2 | 5 | 1 | 7 |
| Withdrew: Other | 1 | 5 | 4 | 1 | 2 | 2 | 2 | 3 | 1 | 1 | 3 |
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis) | -28.9 ± 0.89 | -15.9 ± 1.16 | -15.1 ± 1.19 |
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure | -33.8 ± 1.26 | -37.0 ± 1.26 | -36.8 ± 1.30 | -39.5 ± 1.25 | -36.9 ± 1.27 | -40.1 ± 1.24 | -21.1 ± 1.25 | -27.1 ± 1.25 | -19.8 ± 1.26 | -23.3 ± 1.27 | -24.2 ± 1.23 |
The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|
| Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis) | -28.2 ± 2.49 | -23.4 ± 3.36 | -9.9 ± 2.97 |
The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis) | -27.2 ± 3.21 | -25.4 ± 3.36 | -21.5 ± 3.21 | -31.9 ± 3.61 | -24.8 ± 3.71 | -24.4 ± 3.43 | -12.2 ± 3.22 | -23.4 ± 3.36 | -10.7 ± 3.10 | -11.0 ± 3.04 | -9.9 ± 2.97 |
The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure | -14.4 ± 0.72 | -15.5 ± 0.72 | -15.6 ± 0.74 | -17.0 ± 0.72 | -16.9 ± 0.73 | -18.5 ± 0.71 | -7.4 ± 0.72 | -9.2 ± 0.72 | -6.7 ± 0.72 | -9.2 ± 0.73 | -9.9 ± 0.70 |
The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring. | -13.3 ± 0.80 | -15.0 ± 0.83 | -13.5 ± 0.83 | -17.3 ± 0.85 | -16.5 ± 0.86 | -16.1 ± 0.85 | -6.5 ± 0.79 | -7.5 ± 0.78 | -7.9 ± 0.80 | -7.3 ± 0.79 | -8.9 ± 0.80 |
The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | -24.0 ± 0.97 | -26.7 ± 1.01 | -26.1 ± 1.01 | -30.4 ± 1.03 | -27.9 ± 1.04 | -28.1 ± 1.03 | -10.9 ± 0.96 | -14.7 ± 0.95 | -11.7 ± 0.97 | -12.6 ± 0.96 | -15.3 ± 0.97 |
The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | -13.5 ± 0.60 | -15.0 ± 0.62 | -14.9 ± 0.63 | -17.3 ± 0.64 | -16.5 ± 0.65 | -15.9 ± 0.64 | -5.6 ± 0.59 | -6.7 ± 0.59 | -6.8 ± 0.60 | -7.6 ± 0.59 | -8.8 ± 0.60 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring. | -24.4 ± 1.01 | -27.7 ± 1.05 | -26.7 ± 1.06 | -31.2 ± 1.07 | -28.4 ± 1.09 | -28.5 ± 1.07 | -10.8 ± 1.00 | -14.7 ± 0.99 | -11.7 ± 1.01 | -12.8 ± 1.00 | -15.7 ± 1.01 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring. | -13.7 ± 0.64 | -15.6 ± 0.66 | -15.1 ± 0.66 | -17.6 ± 0.67 | -16.8 ± 0.69 | -16.2 ± 0.67 | -5.6 ± 0.63 | -6.5 ± 0.62 | -6.8 ± 0.64 | -7.7 ± 0.63 | -9.1 ± 0.64 |
The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring. | -22.5 ± 1.09 | -24.0 ± 1.13 | -24.3 ± 1.14 | -28.1 ± 1.15 | -26.5 ± 1.17 | -26.3 ± 1.15 | -11.3 ± 1.08 | -14.4 ± 1.06 | -11.8 ± 1.09 | -11.8 ± 1.08 | -14.2 ± 1.09 |
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring. | -12.8 ± 0.71 | -13.5 ± 0.73 | -14.4 ± 0.74 | -16.2 ± 0.75 | -15.8 ± 0.76 | -14.9 ± 0.75 | -6.0 ± 0.70 | -7.1 ± 0.69 | -6.9 ± 0.70 | -7.5 ± 0.69 | -8.0 ± 0.71 |
The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring. | -24.6 ± 1.07 | -28.0 ± 1.11 | -27.1 ± 1.12 | -31.7 ± 1.13 | -28.5 ± 1.15 | -28.7 ± 1.13 | -10.4 ± 1.06 | -14.5 ± 1.04 | -11.8 ± 1.07 | -12.7 ± 1.05 | -15.8 ± 1.07 |
The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring. | -13.6 ± 0.68 | -15.6 ± 0.71 | -15.4 ± 0.71 | -17.8 ± 0.72 | -16.8 ± 0.73 | -16.2 ± 0.72 | -5.3 ± 0.67 | -6.3 ± 0.66 | -6.8 ± 0.68 | -7.6 ± 0.67 | -9.2 ± 0.68 |
Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline. | 86.4 | 88.9 | 90.3 | 93.5 | 86.8 | 94.9 | 56.1 | 76.9 | 53.5 | 64.5 | 66.7 |
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis) | -22.9 ± 1.19 | -26.3 ± 1.24 | -24.4 ± 1.24 | -29.8 ± 1.26 | -26.3 ± 1.28 | -28.0 ± 1.26 | -12.7 ± 1.18 | -15.9 ± 1.16 | -12.1 ± 1.19 | -12.8 ± 1.17 | -15.1 ± 1.19 |
Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline. | 89.6 | 89.5 | 87.6 | 94.8 | 90.1 | 96.8 | 63.9 | 78.8 | 60.6 | 71.1 | 74.7 |
Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8. | 83.1 | 84.3 | 84.8 | 91.0 | 82.8 | 93.0 | 45.8 | 67.9 | 39.4 | 55.3 | 62.3 |
Collected over Treatment-emergent adverse events are adverse events that started on or after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | — | 3/156 (1.9%) | 52/156 (33.3%) |
| Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | — | 0/154 (0%) | 55/154 (35.7%) |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | — | 1/146 (0.7%) | 40/146 (27.4%) |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | — | 2/156 (1.3%) | 74/156 (47.4%) |
| Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | — | 2/153 (1.3%) | 52/153 (34%) |
| Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | — | 2/161 (1.2%) | 67/161 (41.6%) |
| Chlorthalidone 12.5 mg QD | — | 0/156 (0%) | 51/156 (32.7%) |
| Chlorthalidone 25 mg QD | — | 2/160 (1.3%) | 53/160 (33.1%) |
| Azilsartan Medoxomil 20 mg QD | — | 2/155 (1.3%) | 25/155 (16.1%) |
| Azilsartan Medoxomil 40 mg QD | — | 2/153 (1.3%) | 36/153 (23.5%) |
| Azilsartan Medoxomil 80 mg QD | — | 3/162 (1.9%) | 32/162 (19.8%) |
| Event | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Metabolic encephalopathyNervous system disorders | 0/156 | 0/154 | 1/146 | 0/156 | 0/153 | 0/161 | 0/156 | 0/160 | 0/155 | 0/153 | 0/162 |
| Myocardial ischaemiaCardiac disorders | 0/156 | 0/154 | 0/146 | 0/156 | 0/153 | 0/161 | 0/156 | 0/160 | 1/155 | 1/153 | 0/162 |
| Supraventricular tachycardiaCardiac disorders | 0/156 | 0/154 | 0/146 | 0/156 | 0/153 | 0/161 | 0/156 | 0/160 | 0/155 | 1/153 | 0/162 |
| Non-cardiac chest painGastrointestinal disorders | 0/156 | 0/154 | 0/146 | 0/156 | 0/153 | 0/161 | 0/156 | 0/160 | 0/155 | 1/153 | 0/162 |
| Blood urea increasedInvestigations | 1/156 | 0/154 | 0/146 | 0/156 | 1/153 | 0/161 | 0/156 | 0/160 | 0/155 | 0/153 | 0/162 |
| Blood creatinine increasedInvestigations | 0/156 | 0/154 | 0/146 | 0/156 | 1/153 | 0/161 | 0/156 | 0/160 | 0/155 | 0/153 | 0/162 |
| Blood uric acid increasedInvestigations | 0/156 | 0/154 | 0/146 | 0/156 | 1/153 | 0/161 | 0/156 | 0/160 | 0/155 | 0/153 | 0/162 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/156 | 0/154 | 0/146 | 0/156 | 1/153 | 0/161 | 0/156 | 0/160 | 0/155 | 0/153 | 0/162 |
| Bipolar disorderPsychiatric disorders | 0/156 | 0/154 | 0/146 | 0/156 | 0/153 | 0/161 | 0/156 | 0/160 | 1/155 | 0/153 | 0/162 |
| Suicidal ideationPsychiatric disorders | 0/156 | 0/154 | 0/146 | 0/156 | 0/153 | 0/161 | 0/156 | 0/160 | 1/155 | 0/153 | 0/162 |
| Event | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood creatinine increasedInvestigations | 15/156 | 19/154 | 17/146 | 29/156 | 18/153 | 32/161 | 5/156 | 9/160 | 4/155 | 5/153 | 6/162 |
| DizzinessNervous system disorders | 12/156 | 17/154 | 20/146 | 21/156 | 19/153 | 19/161 | 6/156 | 5/160 | 2/155 | 7/153 | 6/162 |
| HeadacheNervous system disorders | 8/156 | 12/154 | 1/146 | 9/156 | 11/153 | 11/161 | 19/156 | 17/160 | 13/155 | 11/153 | 12/162 |
| HypokalaemiaMetabolism and nutrition disorders | 3/156 | 2/154 | 0/146 | 5/156 | 0/153 | 2/161 | 4/156 | 19/160 | 0/155 | 1/153 | 0/162 |
| Blood creatine phosphokinase increasedInvestigations | 3/156 | 4/154 | 3/146 | 10/156 | 3/153 | 3/161 | 6/156 | 7/160 | 6/155 | 7/153 | 6/162 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/156 | 6/154 | 4/146 | 3/156 | 3/153 | 10/161 | 3/156 | 3/160 | 0/155 | 0/153 | 0/162 |
| Blood uric acid increasedInvestigations | 3/156 | 9/154 | 6/146 | 7/156 | 9/153 | 3/161 | 6/156 | 5/160 | 1/155 | 2/153 | 1/162 |
| Blood urea increasedInvestigations | 1/156 | 6/154 | 4/146 | 8/156 | 6/153 | 9/161 | 0/156 | 4/160 | 0/155 | 0/153 | 1/162 |
| NasopharyngitisInfections and infestations | 8/156 | 5/154 | 2/146 | 7/156 | 2/153 | 3/161 | 6/156 | 4/160 | 2/155 | 7/153 | 2/162 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 8/156 | 2/154 | 0/146 | 6/156 | 2/153 | 4/161 | 2/156 | 0/160 | 2/155 | 0/153 | 2/162 |
| Age Continuous(years) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 58.2 ± 10.57 | 57.4 ± 11.13 | 56.2 ± 10.50 | 57.4 ± 11.07 | 55.8 ± 11.22 | 57.6 ± 11.04 | 57.3 ± 11.30 | 56.2 ± 10.04 | 57.3 ± 11.04 | 57.8 ± 10.28 | 57.3 ± 10.87 | 57.2 ± 10.82 |
| Age, Customized(participants) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <45 years | 15 | 16 | 17 | 21 | 25 | 19 | 21 | 18 | 18 | 17 | 16 | 203 |
| Between 45 to 64 years | 98 | 97 | 100 | 93 | 90 | 104 | 97 | 108 | 97 | 98 | 107 | 1089 |
| ≥65 years | 43 | 41 | 30 | 42 | 38 | 39 | 39 | 33 | 40 | 38 | 39 | 422 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 86 | 77 | 76 | 85 | 82 | 100 | 74 | 90 | 87 | 68 | 84 | 909 |
| Male | 70 | 77 | 71 | 71 | 71 | 62 | 83 | 69 | 68 | 85 | 78 | 805 |
| Ethnicity (NIH/OMB)(Participants) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 19 | 11 | 15 | 19 | 15 | 17 | 19 | 20 | 17 | 15 | 177 |
| Not Hispanic or Latino | 90 | 75 | 76 | 85 | 71 | 87 | 84 | 86 | 77 | 80 | 86 | 897 |
| Unknown or Not Reported | 56 | 60 | 60 | 56 | 63 | 60 | 56 | 54 | 58 | 56 | 61 | 640 |
| Race (NIH/OMB)(participants) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 9 | 13 | 13 | 13 | 12 | 16 | 14 | 14 | 11 | 13 | 14 | 142 |
| Asian | 4 | 3 | 4 | 4 | 2 | 3 | 1 | 7 | 1 | 1 | 4 | 34 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Black or African American | 34 | 28 | 29 | 30 | 26 | 34 | 31 | 29 | 31 | 35 | 35 | 342 |
| White | 111 | 112 | 102 | 111 | 114 | 109 | 111 | 111 | 113 | 105 | 111 | 1210 |
| More than one race | 2 | 2 | 1 | 2 | 1 | 0 | 1 | 2 | 1 | 1 | 2 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Chile | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | 2 | 3 | 2 | 26 |
| Germany | 4 | 6 | 6 | 5 | 6 | 5 | 4 | 5 | 3 | 4 | 5 | 53 |
| Guatemala | 8 | 8 | 9 | 10 | 10 | 8 | 8 | 9 | 8 | 9 | 9 | 96 |
| Mexico | 10 | 11 | 11 | 9 | 12 | 11 | 11 | 8 | 13 | 11 | 12 | 119 |
| Netherlands | 6 | 7 | 6 | 5 | 7 | 5 | 6 | 6 | 6 | 6 | 7 | 67 |
| Peru | 11 | 12 | 13 | 12 | 12 | 14 | 12 | 11 | 13 | 12 | 12 | 134 |
| Poland | 8 | 8 | 7 | 8 | 8 | 8 | 7 | 8 | 8 | 7 | 8 | 85 |
| Russian Federation | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 5 | 4 | 6 | 58 |
| United States | 100 | 94 | 87 | 100 | 90 | 102 | 101 | 105 | 97 | 97 | 101 | 1074 |
| Height(cm) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 166.3 ± 11.71 | 166.6 ± 10.85 | 167.1 ± 11.44 | 166.8 ± 11.64 | 166.6 ± 10.81 | 165.4 ± 10.79 | 168.3 ± 11.07 | 166.1 ± 11.36 | 166.4 ± 10.65 | 167.7 ± 12.27 | 167.1 ± 11.85 | 166.8 ± 11.32 |
| Weight(kg) | Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD | Chlorthalidone 12.5 mg QD | Chlorthalidone 25 mg QD | Azilsartan Medoxomil 20 mg QD | Azilsartan Medoxomil 40 mg QD | Azilsartan Medoxomil 80 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 89.85 ± 22.076 | 86.06 ± 18.056 | 89.28 ± 21.484 | 90.16 ± 21.949 | 87.31 ± 19.209 | 86.44 ± 20.412 | 89.12 ± 21.049 | 86.70 ± 20.270 | 87.27 ± 18.934 | 87.54 ± 19.019 | 86.27 ± 20.354 | 87.80 ± 20.289 |
3 further baseline measures are reported on the registry.
The record gives a start of Jan 2009, a primary completion of May 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone